Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 EUR | -3.17% | -19.31% | -54.48% |
Mar. 25 | Carmat: final agreement with creditors | CF |
Mar. 25 | Carmat Secures Two-year Extensions for Bank Loans | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-54.48% | 83.34M | - | ||
+13.16% | 128B | A- | ||
-8.76% | 10.65B | A- | ||
+3.60% | 8.82B | C | ||
+19.75% | 7.19B | C | ||
+22.28% | 4.99B | B+ | ||
+7.55% | 3.4B | C- | ||
-0.21% | 3.03B | B- | ||
-4.80% | 2.14B | - | - | |
-4.72% | 2B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ALCAR Stock
- Ratings CARMAT